TITLE

Safety of Inhaled Anticholinergics for COPD Scrutinized

AUTHOR(S)
Elliott, William T.
PUB. DATE
November 2008
SOURCE
Primary Care Reports;Nov2008 Pharmacology Watch, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article considers the safety of inhaled anticholinergics for the treatment of chronic obstructive pulmonary disease (COPD), which was prompted by a communication from the U.S. Food and Drug Administration (FDA) regarding the safety review of tiotropium. Two studies linking inhaled anticholinergics tiotropium and ipratropium with increased risk for all-cause mortality and cardiovascular disease in patients with COPD are mentioned.
ACCESSION #
35247314

 

Related Articles

  • Safety of Inhaled Anticholinergics for COPD Scrutinized.  // Neurology Alert;Nov2008 Pharmacology Watch, p1 

    The article reports on the Early Communication issued by the U.S. Food and Drug Administration (FDA) in July 2008 concerning the ongoing safety review of tiotropium drug for the treatment of chronic obstructive pulmonary disease (COPD). Said review aims to investigate the possible association of...

  • Roflumilast: A new phosphodiesterase 4 inhibitor for chronic obstructive pulmonary disease. Baker, Erica L.; Baker, William L. // Formulary;Jan2010, Vol. 45 Issue 1, p6 

    The article discusses the use of roflumilast for the treatment of moderate-to-severe chronic obstructive pulmonary disease (COPD). Roflumilast is a phosphodiesterase 4 inhibitor under review by the U.S. Food and Drug Administration (FDA). Studies demonstrate that roflumilast improves lung...

  • Umeclidinium-vilanterol: First once-daily dual bronchodilator for COPD. YOUNG, CARA ALDRIDGE // Pharmacy Today;Feb2014, Vol. 20 Issue 2, p28 

    The article reports on the approval for umeclidinium-vilanterol powder by the U.S. Food & Drug Administration as a dual bronchodilator for long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). The contraindications of the use of the drug in patients with asthma are...

  • Safety of Inhaled Anticholinergics for COPD Scrutinized.  // OB/GYN Clinical Alert;Nov2008 Pharmacology Watch, p1 

    The article offers news briefs related to pharmacology in the U.S. The Food and Drug Administration (FDA) has issued an "Early Communication" about an ongoing safety review of tiotropium (Spriva®), an inhaled anticholinergic for treating chronic obstructive pulmonary disease (COPD)....

  • Asthma news in 2010. Tanzi, Maria G. // Pharmacy Today;Dec2010, Vol. 16 Issue 12, p36 

    The article discusses various issues related to asthma management in the U.S. Pharmacist Devra Dang states that the general medical community and patients are focusing on assessing asthma control and severity . The Food and Drug Administration (FDA) has released safety communication concerning...

  • Opening the door to new therapeutic options with open label studies for children with detrusor overactivity. Dave, Sumit // Canadian Urological Association Journal;May/Jun2014, Vol. 8 Issue 5/6, p181 

    The author discusses the aspects of the study conducted by scientist G. Nadeau and colleagues on the anticholinergic therapy in children. He mentions the side effects of the optimized drugs during the therapy by the inclusion criteria in which patient not showing the monotherapy. Also mentioned...

  • Comparison of risk of neurovascular and cardiovascular side effects between tiotropium and other anticholinergic agents. Alzayer, Reem; Hughes, Jeffery; Parsons, Richard; Ya Ping Lee // Quality in Primary Care;2010, Vol. 18 Issue 3, p189 

    Aim The aim of this study was to examine the risk of cardiovascular diseases among users of both inhaled (ipratropium bromide or tiotropium bromide) and oral (oxybutynin and propantheline, solifenacin, tolterodine) anticholinergics. Method A retrospective study was undertaken on data obtained...

  • FDA Gives Safety Lowdown.  // Chain Drug Review;7/19/2010, Vol. 32 Issue 12, p69 

    The article reports on the release of summaries of safety reviews for newly approved medicines by the U.S. Food and Drug Administration (FDA).

  • Do inhaled anticholinergics for COPD increase the risk of cardiovascular disease?  // Journal of Family Practice;Dec2008, Vol. 57 Issue 12, p779 

    The article provides facts on the idea that inhaling anticholinergics for chronic obstructive pulmonary disease (COPD) would increase the risk of cardiovascular disease in the U.S. Based on studies, it notes that inhaled anticholinergenics has substantially increased the risk of not only...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics